The full content of Annals is available to subscribers

Subscribe/Learn More  >
Ideas and Opinions |

High-Dose Chemotherapy for Breast Cancer

William J. Gradishar, MD; Martin S. Tallman, MD; and Jeffrey S. Abrams, MD
[+] Article, Author, and Disclosure Information

From Northwestern University, Chicago, Illinois, and the National Cancer Institute, Bethesda, Maryland. Acknowledgment: The authors thank Vicky James for assistance in preparing this manuscript. Grant Support: By 17-96-2-6013 from the Department of Defense (Dr. Gradishar) and R21 CA 64487-01 from the National Cancer Institute. Requests for Reprints: William J. Gradishar, MD, Robert H. Lurie Cancer Center, Northwestern University, 233 East Erie, Suite 700, Chicago, IL 60611. Current Author Addresses: Drs. Gradishar and Tallman: Northwestern University, 233 East Erie, Suite 700, Chicago, IL 60611.

Copyright ©2004 by the American College of Physicians

Ann Intern Med. 1996;125(7):599-604. doi:10.7326/0003-4819-125-7-199610010-00010
Text Size: A A A

The role of high-dose chemotherapy in the management of women with breast cancer remains one of the most controversial issues in oncology. During the past decade, numerous pilot studies have shown the feasibility of administering high-dose chemotherapy followed by autologous bone marrow transplantation or peripheral blood stem-cell transplantation (referred to as high-dose chemotherapy) to women with metastatic disease. However, it appears that survival improves in few treated patients. This treatment strategy is now being evaluated in the adjuvant setting in patients who are at high risk for developing recurrent disease. The National Cancer Institute has selected two randomized, adjuvant breast cancer trials for its High-Priority Clinical Trials Program. These trials are comparing conventional-dose chemotherapy with high-dose chemotherapy in patients in the early stages of breast cancer who are at high risk for disease recurrence.

This paper focuses on the rationale for the randomized studies evaluating adjuvant high-dose chemotherapy in the early stages of breast cancer and reviews the efforts to overcome physician and patient biases so that the trials can be completed.





Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).


Submit a Comment/Letter
Submit a Comment/Letter

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.


Buy Now for $32.00

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Related Articles
Related Point of Care
Topic Collections
PubMed Articles
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.